An automated distinction of DICOM image for lung cancer CAD system

Automated distinction of medical images is an important preprocessing in Computer-Aided Diagnosis (CAD) systems. The CAD systems have been developed using medical image sets with specific scan conditions and body parts. However, varied examinations are performed in medical sites. The specification of the examination is contained into DICOM textual meta information. Most DICOM textual meta information can be considered reliable, however the body part information cannot always be considered reliable. In this paper, we describe an automated distinction of DICOM images as a preprocessing for lung cancer CAD system. Our approach uses DICOM textual meta information and low cost image processing. Firstly, the textual meta information such as scan conditions of DICOM image is distinguished. Secondly, the DICOM image is set to distinguish the body parts which are identified by image processing. The identification of body parts is based on anatomical structure which is represented by features of three regions, body tissue, bone, and air. The method is effective to the practical use of lung cancer CAD system in medical sites

Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study

We conducted a phase II trial of triplet chemotherapy consisting of vinorelbine, gemcitabine, and cisplatin in patients with advanced non-small cell lung cancer to assess its efficacy and toxicity. Thirty-three patients with chemotherapy-naïve stage IIIB disease (n=8), stage IV disease (n=23), or recurrence after surgical resection (n=2) were given intravenous infusions of vinorelbine 25 mg m−2, gemcitabine 1000 mg m−2, and cisplatin 40 mg m−2 on days 1 and 8 at 3-week intervals. There were 16 partial responses, and the objective response rate was 48% (95% confidence interval: 31–66%). The median survival time was 13.5 months (95% confidence interval: 10.6–16.4 months), and the one-year survival rate was 61%. Grade 4 haematologic toxicity consisted of neutropenia in 72% of patients, and febrile neutropenia occurred in 42% of the patients. There was one toxic death, and it was attributed to neutropenic fever and haemoptysis. Autopsy revealed diffuse pulmonary haemorrhage secondary to bacterial abscesses and vasculitis in both lungs. The common nonhaematologic toxicities included grade 2–3 nausea (39%) and vomiting (18%). Triplet chemotherapy containing vinorelbine, gemcitabine, and cisplatin is effective in the treatment of chemo-näive patients with advanced non-small cell lung cancer, but produces unacceptable frequent febrile neutropenia

Malignant inflammation in cutaneous T-cell lymphoma: a hostile takeover

Cutaneous T-cell lymphomas (CTCL) are characterized by the presence of chronically inflamed skin lesions containing malignant T cells. Early disease presents as limited skin patches or plaques and exhibits an indolent behavior. For many patients, the disease never progresses beyond this stage, but in approximately one third of patients, the disease becomes progressive, and the skin lesions start to expand and evolve. Eventually, overt tumors develop and the malignant T cells may disseminate to the blood, lymph nodes, bone marrow, and visceral organs, often with a fatal outcome. The transition from early indolent to progressive and advanced disease is accompanied by a significant shift in the nature of the tumor-associated inflammation. This shift does not appear to be an epiphenomenon but rather a critical step in disease progression. Emerging evidence supports that the malignant T cells take control of the inflammatory environment, suppressing cellular immunity and anti-tumor responses while promoting a chronic inflammatory milieu that fuels their own expansion. Here, we review the inflammatory changes associated with disease progression in CTCL and point to their wider relevance in other cancer contexts. We further define the term "malignant inflammation" as a pro-tumorigenic inflammatory environment orchestrated by the tumor cells and discuss some of the mechanisms driving the development of malignant inflammation in CTCL

Hysteresis loss in a superconducting Bi-2223 tape with fine filaments

The energy loss density was measured for a Bi-2223 tape wire with superconducting filaments of average thickness 2.5 μm to confirm the reduction of energy loss density due to the reversible fluxoid motion. The energy loss density is compared with the prediction by the modified Kim model. It is lower than the prediction at AC field amplitudes below the penetration field at temperatures above 77 K. The slope of the minor magnetization curve is less than unity and the estimated AC penetration depth is longer than the filament thickness in the same regime. This result supports the speculation that the reduction of the energy loss density is due to the reversible fluxoid motio

Fabrication of a working Bi-2223 superconducting magnet cooled by liquid nitrogen

A practical Bi-2223 superconducting magnet, working in liquid nitrogen (L.N2), was designed and fabricated. Bi-2223 tape with a critical current of 147 A was prepared by a controlled overpressure (CT-OP) process at 77.3 K in self-field. Ten double-pancake coils were resistively connected by copper terminals. The bore diameter was 54 mmphi, the magnet outer diameter was 122 mmphi, the height of the magnet was 124 mm, and the weight of the magnet was about 3 kg. The maximum magnetic field at the center of the bore was 0.48 T with an operating current of 50 A. The experimental results agree well with design predictions calculated by finite element method. AC operation was also performed, and no distortion of the voltage waveform was observed. Therefore, this Bi-2223 superconducting magnet is a suitable replacement for copper magnets designed for applications in science and technology